Associated Papers
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
Prete A et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Medullary thyroid carcinoma exclusively associated with a homozygous RET V778I pathogenic variant: a case report with review of literature.
Kihara M et al.
Endocrine Journal, 2026
Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.
Qi XP et al.
Frontiers in Endocrinology, 2026
Decoding genomic rearrangements for cancer driver discovery.
Seo E et al.
Molecules and Cells, 2025
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.
Tabata J et al.
Cancer Research, 2022
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C et al.
International Journal of Molecular Sciences, 2021
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
Elisei R et al.
Genes, 2019
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.
Romei C et al.
Oncotarget, 2018
A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.
Martins-Costa MC et al.
Archives of Endocrinology and Metabolism, 2018
Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.
Lebeault M et al.
Thyroid : Official Journal of the American Thyroid Association, 2017
Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS et al.
The Journal of Clinical Endocrinology and Metabolism, 2017
The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.
Grey W et al.
Endocrine Pathology, 2017
Management of hereditary medullary thyroid carcinoma.
Pappa T et al.
Endocrine, 2016
The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
Pagan M et al.
Bmc Bioinformatics, 2016
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R et al.
European Journal of Endocrinology, 2015
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C et al.
Clinical Endocrinology, 2015
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
Novel RET mutations in macedonian patients with medullary thyroid carcinoma: genotype-phenotype correlations.
Jovanovic R et al.
Prilozi (makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki), 2015
The value of genetic screening in medullary thyroid cancer.
Pappa T et al.
Expert Review of Endocrinology & Metabolism, 2014
Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis.
Nakao KT et al.
Head & Neck, 2013
Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium.
Machens A et al.
European Journal of Endocrinology, 2013
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.
Ciampi R et al.
Molecular and Cellular Endocrinology, 2012
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
Cosci B et al.
Endocrine-related Cancer, 2011
Medullary thyroid cancer: RET testing of an archival material.
Godballe C et al.
European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-rhino-laryngological Societies (eufos) : Affiliated With the German Society for Oto-rhino-laryngology - Head and Neck Surgery, 2010
RET signaling in endocrine tumors: delving deeper into molecular mechanisms.
Lai AZ et al.
Endocrine Pathology, 2007
A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening.
Kaldrymides P et al.
Clinical Endocrinology, 2006
Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.
Machens A et al.
Molecular and Cellular Endocrinology, 2006
Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.
Lesueur F et al.
The Journal of Clinical Endocrinology and Metabolism, 2005
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.
Kouvaraki MA et al.
Thyroid : Official Journal of the American Thyroid Association, 2005
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
Elisei R et al.
The Journal of Clinical Endocrinology and Metabolism, 2004